HCV ANTIVIRAL TESTING IN CHIMPANZEES

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 大约2%的美国人口慢性感染丙型肝炎病毒（HCV）。慢性HCV感染导致严重的肝脏疾病，包括肝硬化和肝癌，约20%的感染者。目前的干扰素和利巴韦林治疗在大多数情况下不能清除病毒。开发改进的抗病毒策略来治疗HCV慢性感染对于控制这种疾病至关重要。本研究的目的是测试一系列小分子抗病毒HCV复制抑制剂在慢性感染HCV的黑猩猩中的疗效。该研究检查了几种不同类型抑制剂的抗病毒活性，并且在PK和疗效研究中检查了每一类抑制剂

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Approximately 2% of the U.S. population is chronically infected with hepatitis C virus (HCV). Chronic HCV infections result in significant liver disease, including cirrhosis and liver cancer in approximately 20% of infected individuals. The current therapy of interferon and ribavirin does not result in viral clearance in the majority of cases. The development of improved antiviral strategies to treat HCV chronic infection is essential for the control of this disease. The objective of this study is to test a series of small molecule antiviral inhibitors of HCV replication for efficacy in chimpanzees chronically infected with HCV. The study has examined antiviral activity from several different classes of inhibitors, and each of the classes has been examined in both PK and efficacy studies